Dark

Check out our API

CRPOF
CEAPRO INC
stock OTC

Inactive

May 31, 2024

0.1700USD-13.041%(-0.0255)6,000

Pre-market

0.00USD-100.000%(-0.20)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 20, 2022

09:05AM EST Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks GlobeNewswire Inc

Nov 29, 2021

08:05AM EST Ceapro Inc. Announces R&D Funding to Support PGX Technology Project GlobeNewswire Inc

Nov 17, 2021

09:00AM EST Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 GlobeNewswire Inc

07:00AM EST Ceapro Inc. Reports Preliminary Results from Clinical Trial GlobeNewswire Inc

Nov 11, 2021

08:35AM EST Ceapro Inc. Provides Update on Development of an Inhalable GlobeNewswire Inc

Nov 10, 2021

09:00AM EST Ceapro Inc. to Present at the Virtual Investor Roundtable Event GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Ceapro Inc. to Present at H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Aug 26, 2021

09:00AM EDT Company continues to increase R&D activities to advanceclinical and preclinical programs GlobeNewswire Inc

Aug 23, 2021

08:05AM EDT Research focused on addressing root cause of disease and tissue damage for diseases such as COVID-19 GlobeNewswire Inc

Aug 11, 2021

09:05AM EDT - Second human trial to be conducted as part of a long-term Master Service Agreement with MHI GlobeNewswire Inc

Jun 1, 2021

04:05PM EDT Ceapro Announces Results of 2021 Shareholders GlobeNewswire Inc

May 26, 2021

08:30AM EDT Clinical study evaluating the well-known health claims of beta glucan and its potentially beneficial approach for patients to lower plasma cholesterol GlobeNewswire Inc

May 20, 2021

09:05AM EDT Maintained production operations during COVID-19 pandemic, providing customers essential products while ensuring the health and safety of Companys employees GlobeNewswire Inc

Apr 22, 2021

09:05AM EDT Ceapro Inc. Reports Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Apr 8, 2021

08:05AM EDT Project significantly advances broadening the application and utility of Ceapros proprietary, first-in-class technologies to develop innovative delivery systems composed of new chemical complexes GlobeNewswire Inc

Mar 3, 2021

09:05AM EST Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences GlobeNewswire Inc

Jan 14, 2021

09:00AM EST Ceapro Inc. to Present at NobleCon17 GlobeNewswire Inc

Jan 8, 2021

08:05AM EST Ceapro Inc. to Present at the H.C. Wainwright BioConnect 2021 GlobeNewswire Inc

Nov 27, 2020

09:00AM EST R&D activities focused on advancing the development of innovative delivery systems and yeast beta glucan as a potential inhalable therapeutic for COVID-19 GlobeNewswire Inc

Oct 22, 2020

08:05AM EDT Ceapro Inc. Announces Increased Financial Contribution from GlobeNewswire Inc

Sep 14, 2020

08:35AM EDT Ceapro Inc. to Present at the H.C. Wainwright 22nd Annual Global GlobeNewswire Inc

Aug 20, 2020

09:05AM EDT Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Companys history GlobeNewswire Inc

Aug 18, 2020

08:05AM EDT First milestone successfully achieved in early stages of the ongoing research project with McMaster University GlobeNewswire Inc

Aug 4, 2020

09:05AM EDT Ceapro Inc. Announces Publication of Positive Results from Study GlobeNewswire Inc

Share